Compare Allstate Corp (ALL) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Canopy Growth Corp — how do they compare? Allstate Corp trades at $256.7 (market cap $66.31B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: Allstate Corp is far larger — about 157.5× Canopy Growth Corp's market cap, and Allstate Corp pays a 1.65% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| ALL | CGC | |
|---|---|---|
Market Cap | $66.31B | $421.10M |
Sector | Financials | Health |
52-Week High | $275.11 | $1.92 |
52-Week Low | $190.00 | $0.86 |
Enterprise Value | $74.96B | $378.55M |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.24, down 4.98% on the day, but remains near recent highs with strong technical support at $253. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, driven by improved underwriting and investment income. Revenue growth has accelerated from $51.4B in 2022 to $67.1B in 2025, with net income margin expanding to 19.19%. Analyst consensus is a Buy with a $266.47 price target, though sentiment is mixed on sustainability of peak profitability.
Outlook is positive given earnings momentum and attractive valuation (P/E 5.25), but risks include potential normalization of underwriting margins and macroeconomic sensitivity. The stock offers value with high ROE (49.11%) and consistent dividend payments, yet investors should weigh cyclical insurance pressures against fundamental strength.
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
